Extending botulinum toxin Type-
A benefits with Argireline Amplified peptide
Cristina Bonell and Gemma Mola of Lipotec explores how the novel hexapeptide Argireline Amplified peptide enhances and prolongs the wrinkle-reducing effects of a popular injectable treatment *
The demand for non-invasive anti-ageing solutions continues to shape innovation in the specialty chemicals sector, particularly in the development of bioactive peptides for cosmetic applications.
Botulinum toxin type-A( BTA) remains a benchmark in aesthetic dermatology, due to its rapid and visible efficacy in reducing dynamic facial wrinkles.
Its mechanism, the disruption of SNARE complex formation in motor neurons leading to acetylcholine inhibition, results in temporary muscle paralysis and wrinkle attenuation. However, the transient nature of BTA’ s effects, typically lasting three to four months, presents a commercial and clinical a
b
Figure 1- Volunteer before & after BTA treatment followed by treatment with placebo cream with surprise( a) & concern( b) expressions
Figure 2- Variations(%) in skin wrinkle coefficient of visibility with time for the different treatments
Note: Forehead: l. s. p < 0.1 vs. placebo at 3 months. Frown: l. s. p < 0.1 at 1 month and **** p < 0.0001 at 4 months vs. initial time. Crow’ s feet: * p > 0.05 at 1 month and *** p > 0.001 at 4 months vs. initial time. Wilcoxon or Student’ s T-test used after checking normality distributions by a Shapiro-Wilk test.
62 SPECIALITY CHEMICALS MAGAZINE ESTABLISHED 1981